Nuvilex Selects Translational Drug Development (TD2) To Advance Treatment For Pancreatic Cancer
4/1/2014 9:41:49 AM
SILVER SPRING, Md., April 1, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), a clinical-stage international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has signed a Master Services Agreement with Translational Drug Development (TD2) pursuant to which TD2 will conduct preclinical and clinical studies in support of the development of Nuvilex's pancreatic cancer and other treatments utilizing Cell-in-a-Box® technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by